Artículos de revistas sobre el tema "Neuroendocrine transdifferentiation"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Neuroendocrine transdifferentiation".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Sergeant, Camille, Christel Jublanc, Delphine Leclercq, Anne-Laure Boch, Franck Bielle, Gerald Raverot, Adrian F. Daly, Jacqueline Trouillas y Chiara Villa. "Transdifferentiation of Neuroendocrine Cells". American Journal of Surgical Pathology 41, n.º 6 (junio de 2017): 849–53. http://dx.doi.org/10.1097/pas.0000000000000803.
Texto completoStone, Louise. "A novel mechanism of neuroendocrine transdifferentiation". Nature Reviews Urology 15, n.º 5 (20 de marzo de 2018): 263. http://dx.doi.org/10.1038/nrurol.2018.40.
Texto completoCordeiro-Rudnisky, Fernanda, Yue Sun y Rayan Saade. "Prostate Carcinoma With Overlapping Features of Small Cell and Acinar Adenocarcinoma: A Case Report". American Journal of Clinical Pathology 152, Supplement_1 (11 de septiembre de 2019): S66—S67. http://dx.doi.org/10.1093/ajcp/aqz113.072.
Texto completoQuintanal-Villalonga, Alvaro, Hirokazu Taniguchi, Yingqian A. Zhan, Jacklynn V. Egger, Umesh Bhanot, Juan Qiu, Elisa de Stanchina et al. "AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in EGFR-mutant lung adenocarcinoma." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e21166-e21166. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21166.
Texto completoYuan, Ta-Chun, Suresh Veeramani y Ming-Fong Lin. "Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells". Endocrine-Related Cancer 14, n.º 3 (septiembre de 2007): 531–47. http://dx.doi.org/10.1677/erc-07-0061.
Texto completoVon Amsberg, Gunhild, Sergey Dyshlovoy, Jessica Hauschild, Verena Sailer, Sven Perner, Anne Offermann, Lina Merkens et al. "Long-term taxane exposure and transdifferentiation of prostate cancer in vitro." Journal of Clinical Oncology 41, n.º 6_suppl (20 de febrero de 2023): 254. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.254.
Texto completoQuintanal-Villalonga, Alvaro, Hirokazu Taniguchi, Yingqian A. Zhan, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah et al. "Abstract 658: AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 658. http://dx.doi.org/10.1158/1538-7445.am2022-658.
Texto completoFrigo, Daniel E. y Donald P. McDonnell. "Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation". Molecular Cancer Therapeutics 7, n.º 3 (marzo de 2008): 659–69. http://dx.doi.org/10.1158/1535-7163.mct-07-0480.
Texto completoPatel, Girijesh, Sayanika Dutta, Mosharaf Mahmud Syed, Sabarish Ramachandran, Monica Sharma, Venkatesh Rajamanickam, Vadivel Ganapathy et al. "TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p". Cancers 13, n.º 19 (7 de octubre de 2021): 5020. http://dx.doi.org/10.3390/cancers13195020.
Texto completoTurner, Leo, Andrew Burbanks y Marianna Cerasuolo. "Mathematical insights into neuroendocrine transdifferentiation of human prostate cancer cells". Nonlinear Analysis: Modelling and Control 26, n.º 5 (1 de septiembre de 2021): 884–913. http://dx.doi.org/10.15388/namc.2021.26.24441.
Texto completoCerasuolo, Marianna, Debora Paris, Fabio A. Iannotti, Dominique Melck, Roberta Verde, Enrico Mazzarella, Andrea Motta y Alessia Ligresti. "Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach". Cancer Research 75, n.º 15 (11 de junio de 2015): 2975–86. http://dx.doi.org/10.1158/0008-5472.can-14-3830.
Texto completoZhu, Shimiao, Hao Tian, Xiaodan Niu, Jiang Wang, Xing Li, Ning Jiang, Simeng Wen et al. "Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer". Oncogene 38, n.º 24 (15 de febrero de 2019): 4875–84. http://dx.doi.org/10.1038/s41388-019-0750-5.
Texto completoZamora, Irene, Michael R. Freeman, Ignacio J. Encío y Mirja Rotinen. "Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer". International Journal of Molecular Sciences 24, n.º 18 (5 de septiembre de 2023): 13673. http://dx.doi.org/10.3390/ijms241813673.
Texto completoZhu, Shimiao, Hao Tian, Xiaodan Niu, Jiang Wang, Xing Li, Ning Jiang, Simeng Wen et al. "Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer". Oncogene 38, n.º 24 (2 de mayo de 2019): 4885. http://dx.doi.org/10.1038/s41388-019-0827-1.
Texto completoWright, Michael E., Ming-Jer Tsai y Ruedi Aebersold. "Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells". Molecular Endocrinology 17, n.º 9 (septiembre de 2003): 1726–37. http://dx.doi.org/10.1210/me.2003-0031.
Texto completoAzur, Romie Angelo G., Kevin Christian V. Olarte, Weand S. Ybañez, Alessandria Maeve M. Ocampo y Pia D. Bagamasbad. "CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer". PLOS ONE 19, n.º 5 (13 de mayo de 2024): e0300413. http://dx.doi.org/10.1371/journal.pone.0300413.
Texto completoSlabáková, Eva, Zuzana Kahounová, Jiřina Procházková y Karel Souček. "Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs". Non-Coding RNA 7, n.º 4 (2 de diciembre de 2021): 75. http://dx.doi.org/10.3390/ncrna7040075.
Texto completoGopal, Priyanka y Mohamed Abazeed. "Abstract 5830: A first-of-its-kind model that reconstitutes targeted drug-induced cellular transdifferentiation". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 5830. http://dx.doi.org/10.1158/1538-7445.am2024-5830.
Texto completoMarzioni, Marco, Stefania Saccomanno, Cinzia Candelaresi, Chiara Rychlicki, Laura Agostinelli, Kumar Shanmukhappa, Luciano Trozzi, Irene Pierantonelli, Samuele De Minicis y Antonio Benedetti. "Pancreatic Duodenal Homeobox-1 de novo expression drives cholangiocyte neuroendocrine-like transdifferentiation". Journal of Hepatology 53, n.º 4 (octubre de 2010): 663–70. http://dx.doi.org/10.1016/j.jhep.2010.04.022.
Texto completoZelivianski, Stanislav, Michael Verni, Carissa Moore, Dmitriy Kondrikov, Rodney Taylor y Ming-Fong Lin. "Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1539, n.º 1-2 (mayo de 2001): 28–43. http://dx.doi.org/10.1016/s0167-4889(01)00087-8.
Texto completoLi, Yinan, Nilgun Donmez, Cenk Sahinalp, Ning Xie, Yuwei Wang, Hui Xue, Fan Mo et al. "SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition". European Urology 71, n.º 1 (enero de 2017): 68–78. http://dx.doi.org/10.1016/j.eururo.2016.04.028.
Texto completoClermont, Pier-Luc, Xinpei Ci, Hardev Pandha, Yuzhuo Wang y Francesco Crea. "Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines". International Journal of Endocrine Oncology 6, n.º 2 (1 de septiembre de 2019): IJE20. http://dx.doi.org/10.2217/ije-2019-0008.
Texto completoCi, Xinpei, Jun Hao, Xin Dong, Hui Xue, Rebecca Wu, Stephen Yiu Chuen Choi, Anne M. Haegert et al. "Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development". Cells 9, n.º 6 (4 de junio de 2020): 1398. http://dx.doi.org/10.3390/cells9061398.
Texto completoOstano, Paola, Maurizia Mello-Grand, Debora Sesia, Ilaria Gregnanin, Caterina Peraldo-Neia, Francesca Guana, Elena Jachetti, Antonella Farsetti y Giovanna Chiorino. "Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma". International Journal of Molecular Sciences 21, n.º 3 (6 de febrero de 2020): 1078. http://dx.doi.org/10.3390/ijms21031078.
Texto completoFernandes, Rayzel C., John Toubia, Scott Townley, Adrienne R. Hanson, B. Kate Dredge, Katherine A. Pillman, Andrew G. Bert et al. "Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer". Cell Reports 34, n.º 1 (enero de 2021): 108585. http://dx.doi.org/10.1016/j.celrep.2020.108585.
Texto completoYao, Erica, Chuwen Lin, Qingzhe Wu, Kuan Zhang, Hai Song y Pao-Tien Chuang. "Notch Signaling Controls Transdifferentiation of Pulmonary Neuroendocrine Cells in Response to Lung Injury". STEM CELLS 36, n.º 3 (1 de diciembre de 2017): 377–91. http://dx.doi.org/10.1002/stem.2744.
Texto completoPisani, David, Daniel Micallef, Jeanesse Scerri, Alexandra Betts, James Degaetano y Shawn Baldacchino. "Neuroendocrine Transdifferentiation in Cutaneous Melanoma: A Case Report and Review of the Literature". American Journal of Dermatopathology 45, n.º 4 (17 de febrero de 2023): 264–68. http://dx.doi.org/10.1097/dad.0000000000002377.
Texto completoMoritz, Tom, Simone Venz, Heike Junker, Sarah Kreuz, Reinhard Walther y Uwe Zimmermann. "Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells". Tumor Biology 37, n.º 8 (5 de febrero de 2016): 10435–46. http://dx.doi.org/10.1007/s13277-016-4925-1.
Texto completoZhu, Shimiao, Zhiqun Shang, Hao Tian, Amilcar Flores-Morales y Yuanjie Niu. "AB007. Neurotensin derived from cancer stroma contributes to castration resistance via promoting neuroendocrine transdifferentiation". Translational Andrology and Urology 5, S1 (abril de 2016): AB007. http://dx.doi.org/10.21037/tau.2016.s007.
Texto completoMendieta, Irasema, Maricela Rodríguez-Nieto, Rosa Elvira Nuñez-Anita, Jorge Luis Menchaca-Arredondo, Guadalupe García-Alcocer y Laura Cristina Berumen. "Ultrastructural changes associated to the neuroendocrine transdifferentiation of the lung adenocarcinoma cell line A549". Acta Histochemica 123, n.º 8 (diciembre de 2021): 151797. http://dx.doi.org/10.1016/j.acthis.2021.151797.
Texto completoOELRICH, FELIX, HEIKE JUNKER, MATTHIAS B. STOPE, HOLGER H. H. ERB, REINHARD WALTHER, SIMONE VENZ y UWE ZIMMERMANN. "Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery". Anticancer Research 41, n.º 8 (19 de julio de 2021): 3717–29. http://dx.doi.org/10.21873/anticanres.15163.
Texto completoTurner, Leo, Andrew Burbanks y Marianna Cerasuolo. "PCa dynamics with neuroendocrine differentiation and distributed delay". Mathematical Biosciences and Engineering 18, n.º 6 (2021): 8577–602. http://dx.doi.org/10.3934/mbe.2021425.
Texto completoDankert, Jaroslaw Thomas, Marc Wiesehöfer, Elena Dilara Czyrnik, Bernhard B. Singer, Nicola von Ostau y Gunther Wennemuth. "The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells". PLOS ONE 13, n.º 7 (12 de julio de 2018): e0200472. http://dx.doi.org/10.1371/journal.pone.0200472.
Texto completoAngelucci, A., P. Muzi, G. Pace, L. Cristiano, A. M. Cimini, M. P. Ceru, C. Vicentini y M. Bologna. "513 NEUROENDOCRINE TRANSDIFFERENTIATION INDUCED BY HDAC INHIBITORS CONFERS RESISTANCE TO ANTIBLASTIC THERAPY IN PROSTATE CARCINOMA". European Urology Supplements 8, n.º 4 (marzo de 2009): 249. http://dx.doi.org/10.1016/s1569-9056(09)60509-1.
Texto completoBURCHARDT, TATJANA, MARTIN BURCHARDT, MIN-WEI CHEN, YICHEN CAO, ALEXANDRE DE LA TAILLE, AHMED SHABSIGH, OMAR HAYEK, THAMBI DORAI y RALPH BUTTYAN. "TRANSDIFFERENTIATION OF PROSTATE CANCER CELLS TO A NEUROENDOCRINE CELL PHENOTYPE IN VITRO AND IN VIVO". Journal of Urology 162, n.º 5 (noviembre de 1999): 1800–1805. http://dx.doi.org/10.1016/s0022-5347(05)68241-9.
Texto completoBraadland, Peder R., Håkon Ramberg, Helene Hartvedt Grytli, Alfonso Urbanucci, Heidi Kristin Nielsen, Ingrid Jenny Guldvik, Andreas Engedal et al. "The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells". Molecular Cancer Research 17, n.º 11 (8 de agosto de 2019): 2154–68. http://dx.doi.org/10.1158/1541-7786.mcr-18-0605.
Texto completoKim, Soojin, Daksh Thaper, Samir Bidnur, Paul Toren, Shusuke Akamatsu, Jennifer L. Bishop, Colin Colins, Sepideh Vahid y Amina Zoubeidi. "PEG10 is associated with treatment-induced neuroendocrine prostate cancer". Journal of Molecular Endocrinology 63, n.º 1 (julio de 2019): 39–49. http://dx.doi.org/10.1530/jme-18-0226.
Texto completoInoue, Y. y W. Lockwood. "MA22.02 Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer". Journal of Thoracic Oncology 13, n.º 10 (octubre de 2018): S433—S434. http://dx.doi.org/10.1016/j.jtho.2018.08.502.
Texto completoPernicová, Zuzana, Eva Slabáková, Radek Fedr, Šárka Šimečková, Josef Jaroš, Tereza Suchánková, Jan Bouchal et al. "The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells". Molecular Cancer 13, n.º 1 (2014): 113. http://dx.doi.org/10.1186/1476-4598-13-113.
Texto completoShen, Ruoqian, Thambi Dorai, Matthias Szaboles, Aaron E. Katz, Carl A. Olsson y Ralph Buttyan. "Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium". Urologic Oncology: Seminars and Original Investigations 3, n.º 2 (marzo de 1997): 67–75. http://dx.doi.org/10.1016/s1078-1439(97)00039-2.
Texto completoIndo, Sebastián, Octavio Orellana-Serradell, María José Torres, Enrique A. Castellón y Héctor R. Contreras. "Overexpression of REST Represses the Epithelial–Mesenchymal Transition Process and Decreases the Aggressiveness of Prostate Cancer Cells". International Journal of Molecular Sciences 25, n.º 6 (15 de marzo de 2024): 3332. http://dx.doi.org/10.3390/ijms25063332.
Texto completoZhao, Kaihong. "Attractor of a nonlinear hybrid reaction–diffusion model of neuroendocrine transdifferentiation of human prostate cancer cells with time-lags". AIMS Mathematics 8, n.º 6 (2023): 14426–48. http://dx.doi.org/10.3934/math.2023737.
Texto completoVlachostergios, Panagiotis J., Athanasios Karathanasis y Vassilios Tzortzis. "Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival". Genes 13, n.º 1 (13 de enero de 2022): 135. http://dx.doi.org/10.3390/genes13010135.
Texto completoBishop, Jennifer L., Alastair Davies, Kirsi Ketola y Amina Zoubeidi. "Regulation of tumor cell plasticity by the androgen receptor in prostate cancer". Endocrine-Related Cancer 22, n.º 3 (1 de mayo de 2015): R165—R182. http://dx.doi.org/10.1530/erc-15-0137.
Texto completoDavidoff, Michail S., Ralf Middendorff, Grigori Enikolopov, Dieter Riethmacher, Adolf F. Holstein y Dieter Müller. "Progenitor cells of the testosterone-producing Leydig cells revealed". Journal of Cell Biology 167, n.º 5 (29 de noviembre de 2004): 935–44. http://dx.doi.org/10.1083/jcb.200409107.
Texto completoSivanandhan, Dhanalakshmi, Sridharan Rajagopal, Chandru Gajendran, Naveen Sadhu, Mohd Zainuddin, Ramachandraiah Gosu y Luca Rastelli. "Abstract B029: LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types". Cancer Research 82, n.º 23_Supplement_2 (1 de diciembre de 2022): B029. http://dx.doi.org/10.1158/1538-7445.cancepi22-b029.
Texto completoQiao, Yuanyuan, Chungen Li, Yang Zheng, Xia Jiang, Sarah Nicole Yee, Caleb Cheng, Yi Bao et al. "Abstract 2898: Development of the lipid kinase PIKfyve PROTAC degrader against neuroendocrine prostate cancer". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 2898. http://dx.doi.org/10.1158/1538-7445.am2024-2898.
Texto completoBae, Song Yi, Hannah E. Bergom, Abderrahman Day, Joseph T. Greene, Tanya S. Freedman, Justin H. Hwang y Justin M. Drake. "Abstract B057: ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer". Cancer Research 83, n.º 11_Supplement (2 de junio de 2023): B057. http://dx.doi.org/10.1158/1538-7445.prca2023-b057.
Texto completoSyder, A. J., S. M. Karam, J. C. Mills, J. E. Ippolito, H. R. Ansari, V. Farook y J. I. Gordon. "A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype". Proceedings of the National Academy of Sciences 101, n.º 13 (30 de marzo de 2004): 4471–76. http://dx.doi.org/10.1073/pnas.0307983101.
Texto completoAngelucci, Adriano, Paola Muzi, Loredana Cristiano, Danilo Millimaggi, AnnaMaria Cimini, Vincenza Dolo, Roberto Miano, Carlo Vicentini, Maria Paola Cerù y Mauro Bologna. "Neuroendocrine transdifferentiation induced by VPA is mediated by PPARγ activation and confers resistance to antiblastic therapy in prostate carcinoma". Prostate 68, n.º 6 (1 de mayo de 2008): 588–98. http://dx.doi.org/10.1002/pros.20708.
Texto completo